# Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

> **NCT00095940** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (actual)

## Conditions studied

- Recurrent Childhood Anaplastic Astrocytoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Giant Cell Glioblastoma
- Recurrent Childhood Glioblastoma
- Recurrent Childhood Gliosarcoma
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Oligodendroglioma

## Interventions

- **DRUG:** lapatinib ditosylate
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** magnetic resonance imaging

## Key facts

- **NCT ID:** NCT00095940
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095940, "Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00095940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*